Prostate cancer diagnosis and management

Lancet

Volumn 349, Issue 9066, 1997, Pages 1681-1687

  Frydenberg, Mark ^a   Stricker, Philip D ^b   Kaye, Keith W ^c  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; HORMONE; PROSTATE SPECIFIC ANTIGEN;

BONE SCINTISCANNING; CANCER SCREENING; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0031007690     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)07393-X     Document Type: Review

References (29)

1. Lange PH, Ercole CJ, Lightner DJ, et al. The value of serum PSA determinations before and after radical prostatectomy. J Urol 1989; 141: 873-79.
2. Partin AW, Oesterling JE. The clinical usefulness of PSA: update 1994. J Urol 1994; 152: 1358-68.
3. Oesterling JE. Molecular PSA: the next frontier in Pca screening. Contemp Urol 1996; 8: 76-92.
4. Rosen MA. Impact of PSA screening on the natural history of prostate cancer. Urology 1995; 46: 757-68.
5. Aus G. Prostate cancer: mortality and morbidity after noncurative treatment. Scand J Urol Nephrol Suppl 1994; 167: 1-41.
6. Catalona WJ, Richie HP, Ahmann FR, et al. Comparisons of DRE and serum PSA in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994; 151: 1283-90.
7. Brawer MK. The diagnosis of prostatic carcinoma. Cancer 1993; 71 (suppl): 899-905.
8. Hricak H, Dooms GC, Jeffrey RB, et al. Prostatic carcinoma: staging by clinical assessment, CT and MR imaging. Radiology 1987; 162: 331-36.
9. Partin AW, Yoo J, Carter HB, et al. The use of PSA, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 1101-14.
10. Bishoff TJ, Reyes A, Thompson IM, et al. Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. Urology 1995; 45: 270-74.
11. Oesterling JE. Using PSA to eliminate the staging radionuclide bone scan: significant economic implications. Urol Clin North Am 1993; 20: 705-11.
12. Walsh PC. Prostate cancer kills: strategy to reduce deaths. Urology 1994; 44: 463-66.
13. Johansson JE. Expectant management of early stage prostatic cancer: Swedish experience. J Urol 1994; 152: 1753-56.
14. Aus G, Hugosson J, Norlen L. Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. J Urol 1995; 154: 466-69.
15. Hancock SL, Cox RS, Bagshaw MA. Prostate specific antigen after radiotherapy for prostate cancer: a re-evaluation of long term biochemical control and the kinetics of recurrence in patients treated at Stanford University. J Urol 1995; 154: 1412-17.
16. Shipley WU, Zietman AL, Hanks GE, et al. Treatment related sequelae following external beam radiation for prostate cancer: a review with an update in patients with stages T1 and T2 tumor. J Urol 1994; 152: 1799-805.
17. 125Iodine implantation for localized prostate cancer using percutaneous approach. J Urol 1995; 153: 1020-25.
18. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994; 152: 1831-36.
19. Zincke H, Oesterling JE, Blute ML, et al. Long term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152: 1850-57.
20. Litwin MS, Hays RD, Fink A, et al. Quality of life outcomes in men treated for localized prostate cancer. JAMA 1995; 273: 129-35.
21. Zagars GK, Johnson DE, Von Eschenbach AC, Hussey DH. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 1988; 14: 1085.
22. Bagshaw MA, Cox RS, Ray GR. Status of radiation treatment of prostate cancer at Stanford University. Natl Cancer Inst Monogr 1988; 7: 47.
23. Van den Ouden D, Davidson PJT, Hop W, Schroeder FH. Radical prostatectomy as monotherapy for locally advanced (stage T3) prostate cancer. J Urol 1994; 151: 646-51.
24. Soloway MS, Shafiri R, Wajsman Z, et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol 1995; 154: 424-28.
25. Kirk D. Immediate versus deferred treatment for advanced disease. Cancer Surv 1995; 23: 183-90.
26. Vogelzang NJ, Chodak GW, Soloway MS, et al. Zoladex Prostate Study Group. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urology 1995; 46: 220-26.
27. McLeod DG. Drawing new conclusions about maximum androgen blockade for advanced Pca. Contemp Urol 1996; 8: 19-31.
28. Bos SD. An overview of current clinical experience with strontium-89 (Metastron). Prostate Suppl 1994; 5: 23-26.
29. Dupont A, Gomez JL, Cusan L, et al. Response to glutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993; 150: 908-13.